Biotie Therapies - Company Announcement

Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE  September 14, 2009
at 1 p.m.


Biotie starts clinical study with phosphodiesterase 4 inhibitor
ELB353

Biotie has started a clinical trial with its phosphodiesterase 4
(PDE4) inhibitor ELB353, having received the prerequisite regulatory
and ethical clearances for the clinical trial application.

The study will be conducted within the European Union and will
evaluate the safety, tolerability, pharmacodynamics and
pharmacokinetics of repeated doses of oral ELB353 in up to 48 healthy
volunteers. The study is expected to provide proof of pharmacodynamic
activity in humans, corroborate the safety profile and establish dose
ranges for further therapeutic studies. Results are expected in the
first half of 2010.

ELB353 is a once-daily, oral PDE4 inhibitor with therapeutic
potential in chronic inflammatory disorders, particularly in chronic
obstructive pulmonary disease (COPD), a serious disorder with major
unmet medical need.


Turku, September 14, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO

For further information, please contact:

Antero Kallio, Chief Medical Officer
Tel. +358 2 274 8900, e-mail: antero.kallio@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central
nervous system and inflammatory diseases. It has a broad range of
innovative small molecule and biological drug candidates at different
stages of clinical and pre-clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential, including addiction and psychotic disorders, rheumatoid
arthritis, psoriasis and chronic obstructive pulmonary disease
(COPD). The most advanced product, nalmefene for alcohol dependence,
is currently in phase III clinical development by licensing partner
H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through
existing alliances with top-tier global pharmaceutical companies such
as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland
and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com